Price
No data yet.
Social Signal Score
Analyst Ratings
14 analystsRevenue
$396.75M+111.05%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Daniel Bendheim
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 2,605
- Beta
- 0.47
- Country
- US
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 3.02
Financials
Revenue
$396.75M+111.1%Net Income
$21.71M+78.3%EBITDA
$55.87M+90.0%Free Cash Flow
$5.22M-66.4%EPS (diluted)
$0.53+71.0%Shares Outstanding (diluted)
41.00M+2.7%Operating Expenses
$86.24MCash & Debt
$81.99MReturn of Capital
$4.87MRevenue by Segment (annual)
$156.42MDividend per Share
$0.12Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $1.52B | $99.72M | $2.46 |
| 2025 | $1.30B | $48.26M | $1.19 |
| 2024 | $1.02B | $2.42M | $0.06 |
| 2023 | $977.89M | $32.61M | $0.81 |
| 2022 | $942.26M | $49.17M | $1.21 |
| 2021 | $833.35M | $54.38M | $1.34 |
| 2020 | $800.35M | $33.55M | $0.83 |
| 2019 | $828.00M | $54.70M | $1.35 |
| 2018 | $820.00M | $64.90M | $1.61 |
| 2017 | $764.30M | $64.60M | $1.63 |
| 2016 | $751.50M | $82.70M | $2.11 |
| 2015 | $748.59M | $60.28M | $1.55 |
| 2014 | $691.90M | $-3.10M | $-0.10 |
| 2013 | $653.15M | $24.89M | $0.82 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from PAHC's reported EPS growth of 8.8% a year over 13 years.
- EPS in 5 years
- $3.74
- Implied price
- $48.68
- Return from $35.45
- 6.5% a year
To earn 15.0% a year on these assumptions you'd need to buy at $24.20 — -31.7% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 9 | 11 | 13 | 15 | 17 |
|---|---|---|---|---|---|
| -1.2% | -10.1% | -6.4% | -3.2% | -0.4% | 2.1% |
| 3.8% | -5.6% | -1.7% | 1.7% | 4.6% | 7.3% |
| 8.8% | -1.0% | 3.0% | 6.5% | 9.6% | 12.4% |
| 13.8% | 3.5% | 7.8% | 11.4% | 14.7% | 17.6% |
| 18.8% | 8.1% | 12.5% | 16.3% | 19.7% | 22.8% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
70+40.00%Social Signal Score
Mentions (9)
- Newszacks.com·14d ago·Positive
Best Momentum Stocks to Buy for September 21st SEI, SDRL and PAHC made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on September 21st, 2026.
View source ↗ - Newszacks.com·17d ago·Positive
PAHC vs. HAE: Which Stock Should Value Investors Buy Now? Investors interested in stocks from the Medical - Products sector have probably already heard of Phibro Animal Health (PAHC) and Haemonetics (HAE). But which of these two stocks presents investors with the better value opportunity right now?
View source ↗ - Newszacks.com·33d ago·Neutral
PAHC or LMAT: Which Is the Better Value Stock Right Now? Investors interested in stocks from the Medical - Products sector have probably already heard of Phibro Animal Health (PAHC) and LeMaitre Vascular (LMAT). But which of these two stocks is more attractive to value investors?
View source ↗ - Newsdefenseworld.net·38d ago·Negative
Phibro Animal Health Q4 Earnings Call Highlights Phibro Animal Health (NASDAQ: PAHC) reported record fiscal 2026 sales and a sharp increase in adjusted EBITDA, supported by growth in its Animal Health and Mineral Nutrition businesses, the integration of its acquired Zoetis medicated feed additive portfolio, and operational initiatives under its Phibro Forward program. For the fiscal year ended June 30, 2026, Phibro posted
View source ↗ - Newsseekingalpha.com·39d ago·Positive
Phibro Animal Health Corporation (PAHC) Q4 2026 Earnings Call Transcript Phibro Animal Health Corporation (PAHC) Q4 2026 Earnings Call Transcript
View source ↗ - Newszacks.com·40d ago·Neutral
Phibro (PAHC) Reports Q4 Earnings: What Key Metrics Have to Say Although the revenue and EPS for Phibro (PAHC) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
View source ↗ - Newsbusinesswire.com·40d ago·Negative
…lth Corporation Reports Fourth Quarter and Fiscal Year Results, Provides Financial Guidance TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) (“Phibro” or the “Company”) today announced financial results for its fourth quarter and fiscal year ended June 30, 2026 and provided its financial guidance for the fiscal year ending June 30, 2027. Highlights for the three months ended June 30, 2026 (compared to the three months ended June 30, 2025) – Net sales of $396.7 mill…
View source ↗ - Newszacks.com·45d ago·Negative
Phibro (PAHC) Q4 Earnings Preview: What You Should Know Beyond the Headline Estimates Besides Wall Street's top-and-bottom-line estimates for Phibro (PAHC), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2026.
View source ↗ - Newsbusinesswire.com·47d ago·Neutral
…poration to Host Webcast and Conference Call on Fourth Quarter and Fiscal Year 2026 Results TEANECK, N.J.--(BUSINESS WIRE)--Phibro Animal Health Corporation (Nasdaq: PAHC) expects to announce its fourth quarter and fiscal year 2026 financial results on Wednesday, August 26, 2026, after the market closes. Phibro management will host a conference call and webcast on Thursday, August 27, 2026, at 9:00 AM Eastern Time. Interested parties are invited to listen to the conference call and view the pres…
View source ↗
Earnings
Wed, Nov 4(in 4 weeks)
Consensus estimate $0.77 per share
Typical surprise +21.2% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 26$0.85 vs $0.71beat
- Wed, May 6$0.76 vs $0.72beat
- Wed, Feb 4$0.87 vs $0.69beat
- Wed, Nov 5$0.73 vs $0.59beat
- Wed, Aug 27$0.57 vs $0.52beat
- Wed, May 7$0.63 vs $0.52beat
Estimates and results for PAHC via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by PAHC officers and directors.
- Bought
- $318k
- Sold
- $20.6m
1 trade
71 trades
- Corcoran E Thomasbought
- Bendheim Jacksold
- Bendheim Jacksold
- Bendheim Jacksold
- Bendheim Jacksold
- Bendheim Jacksold
- Bendheim Jacksold
- Bendheim Jacksold
28 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Michael T. McCaulhouse · TX10 · disclosed Oct 13, 2022 (42d later)Sell$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Oct 13, 2022 (42d later)Sell$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Sep 19, 2022 (20d later)Sell$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Sep 19, 2022 (20d later)Sell$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Apr 18, 2022 (47d later)Sell$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Apr 18, 2022 (47d later)Sell$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Apr 18, 2022 (45d later)Sell$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Apr 18, 2022 (45d later)Sell$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Jan 27, 2022 (44d later)Sell$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Apr 19, 2021 (46d later)Buy$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Apr 19, 2021 (46d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.